Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon in chronic myeloid leukaemia: past and future.
Guilhot F, Roy L, Saulnier PJ, Guilhot J. Guilhot F, et al. Among authors: guilhot j. Best Pract Res Clin Haematol. 2009 Sep;22(3):315-29. doi: 10.1016/j.beha.2009.10.005. Best Pract Res Clin Haematol. 2009. PMID: 19959083 Review.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: guilhot j. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F; CML French Group. Gardembas M, et al. Among authors: guilhot f, guilhot j. Blood. 2003 Dec 15;102(13):4298-305. doi: 10.1182/blood-2003-04-1010. Epub 2003 Aug 21. Blood. 2003. PMID: 12933584 Free article. Clinical Trial.
Interferon therapy in chronic myelogenous leukemia.
Guilhot F, Roy L, Guilhot J, Millot F. Guilhot F, et al. Among authors: guilhot j. Hematol Oncol Clin North Am. 2004 Jun;18(3):585-603, viii. doi: 10.1016/j.hoc.2004.03.002. Hematol Oncol Clin North Am. 2004. PMID: 15271394 Review.
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F. Roy L, et al. Among authors: guilhot f, guilhot j. Blood. 2006 Sep 1;108(5):1478-84. doi: 10.1182/blood-2006-02-001495. Epub 2006 Apr 20. Blood. 2006. PMID: 16627756 Free article.
336 results